オプションチェーンは、Elicio Therapeuticsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Elicio Therapeuticsの市場センチメントを評価します。.

Elicio Therapeutics (NASDAQ:ELTX) 株価情報, オプションチェーン

Elicio Therapeutics

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.

Elicio Therapeutics Inc

C3.Ai Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) shares are rising Thursday after the company reported better-than-expected results for the fourth quarter. The company also announced that the U.S. Air Force raised its contract ceiling <a href="https://www.benzinga.com/pressreleases/25/05/b45668411/c3-ai-u-s-air-force-rapid-sustainment-office-contract-award-increased-to-450-million">to $450 million</a>.
What Happened: C3 AI reported fourth-quarter revenue of $108.7 million, beating&nbsp;<a href="http://benzinga.com/quote/AI/earnings" target="_blank" rel="noreferrer noopener">estimates</a>&nbsp;of $107.73 million. The company reported an adjusted loss of 18 cents per share, beating estimates for a loss of 20 cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Total revenue increased 26% year-over-year as subscription revenue jumped 9% year-over-year. C3 AI noted that it renewed and expanded its strategic partnership with Baker Hughes through a multi-year agreement.
The company closed out the quarter with $742.7 million in cash, cash equivalents and marketable securities.
"The Enterprise AI market is converging toward AI applications — a category we created and continue to lead. We continue to innovate, most recently in agentic AI. We continue to grow, expanding our partner ecosystem and global reach. And we are ready to scale as demand for AI applications accelerates,&#8221; said&nbsp;Thomas Siebel, chairman and CEO of C3 AI.
C3.AI guided for first-quarter revenue of $100 million to $109 million versus estimates of $105 million. The company expects fiscal-year 2026 revenue to be in the range of $447.5 million to $484.5 million, versus estimates of $467.19 million.
C3 AI shares are also getting a boost Thursday morning after the company announced the U.S. Air Force Rapid Sustainment Office (RSO) raised the contract ceiling with the company to&nbsp;$450 million&nbsp;through October 2029, up from $100 million.
The initial $100 million has already been fully utilized to deploy the predictive maintenance platform PANDA, the company said.
&#8220;We believe our program with RSO may be the largest production AI deployment in the U.S. DoD today. At the scale of the U.S. Air Force, this system has the potential to increase aircraft availability by up to&nbsp;25%,&#8221; said Ed Abbo, chief technology officer of C3 AI. 
AI Price Action: <a href="http://benzinga.com/quote/AI" target="_blank" rel="noreferrer noopener">C3.AI shares</a> were up 17.1% at $26.91 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/media/25/05/45664231/teslas-optimus-may-be-the-first-humanoid-robot-to-achieve-high-volume-and-tech-scale-says-nvidia-ceo-jensen-huang-likely-to-be-the-next-multi-trillion-dollar-industry">Tesla&#8217;s Optimus May Be The First Humanoid Robot To Achieve High Volume And Tech Scale, Says Nvidia CEO Jensen Huang: &#8216;&#8230; Likely To Be The Next Multi-Trillion Dollar Industry&#8217;</a></li>
</ul>
Photo: Poetra.RH/Shutterstock.

Earnings

News

Guidance

Contracts

Movers

C3 AI Stock Is Soaring Today: Here's Why

The Goodyear Tire &amp; Rubber Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GT#NASDAQ">GT</a>) ("Goodyear" or the "company") today announced that it has commenced a public offering of&nbsp;$500 million&nbsp;aggregate principal amount of 5-year senior notes (the "notes"). The notes will be senior unsecured obligations of the company. Issuance and sale of the notes is subject to market and other customary closing conditions.
Goodyear intends to use the net proceeds from this offering, together with its current cash and cash equivalents, to redeem in full the company's remaining 5.000% Senior Notes due 2026 (the "2026 Notes"). Currently, there is $900 million&nbsp;in aggregate principal amount of the 2026 Notes outstanding. On May 29, 2025, the company issued a notice of redemption to the holders of the 2026 Notes for $400 million of the 2026 Notes, which we intend to fund using a portion of the cash proceeds from the Dunlop brand disposition. The redemption date for the redemption of the $400 million of 2026 Notes is June 30, 2025. This press release does not constitute a notice of redemption under the optional redemption provisions of the indenture governing the 2026 Notes.

Goodyear Tire & Rubber Commences Public Offering Of $500M Aggregate Principal Amount Of 5-Yr Senior Notes

Best Buy Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) is <a href="https://www.benzinga.com/premarket" target="_blank" rel="noreferrer noopener">trading lower</a> Thursday after the retailer&#8217;s first-quarter 2026 earnings <a href="https://www.benzinga.com/markets/equities/25/05/45592571/best-buy-q1-earnings-preview-analyst-flags-tariff-fallout-cuts-fy25-outlook-amid-profit-risk" target="_blank" rel="noreferrer noopener">fell short of expectations</a>.
The company&#8217;s first-quarter sales fell around 1% (comparable sales fell 0.7%) year over year to $8.77 billion. It missed the analyst <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate of $9.22 billion.</a>
<ul class="wp-block-list">
<li>Domestic revenue of $8.13 billion decreased 0.9%, primarily due to a 0.7% decline <a href="https://www.benzinga.com/pressreleases/25/05/b45665488/best-buy-reports-first-quarter-results" target="_blank" rel="noreferrer noopener">in comparable sales</a>.</li>
<li>The largest drivers of the comparable sales decline on a weighted basis were home theater, appliances, and drones, partially offset by growth in the computing, mobile phone, and tablet categories.</li>
<li>Domestic online revenue of $2.58 billion increased 2.1% on a comparable basis, and as a percentage of total Domestic revenue, online revenue was 31.7% versus 30.8% last year..</li>
</ul>
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44797563/goldman-sachs-sees-upside-in-retail-giants-dollar-tree-home-depot-best-buy-and-target-despite-tariff-margin-pressures" target="_blank" rel="noreferrer noopener">Goldman Sachs Sees Upside In Retail Giants Dollar Tree, Home Depot, Best Buy And Target</a>
The gross profit margin remained unchanged at 23%, and the operating margin fell from 3.5% to 2.5%.
Best Buy reported adjusted earnings of $1.15, missing the consensus of $1.31.
Corie Barry, Best Buy CEO, said the company &#8220;delivered in-line revenue and better-than-expected adjusted operating income."
Outlook: "Today we are updating our full year guidance to incorporate the impact of tariffs," said Matt Bilunas, Best Buy CFO. "We expect annual comparable sales growth to be in the range of down 1% to up 1%, and our adjusted operating income rate to be similar to last year at approximately 4.2%.
For Q2 FY26, Bilunas expects comparable sales to be slightly down to last year. He added that the company&#8217;s adjusted operating income rate will be approximately 3.6.
Best Buy lowered its fiscal 2026 adjusted earnings from $6.20-$6.60 per share to $6.15-$6.30 per share versus consensus of $6.13 per share.
The company lowered its sales guidance from $41.4 billion to $42.2 billion to $41.1 billion to $41.9 billion. The consensus hovers around $41.44 billion.
The guidance reflects comparable sales of (1.0%) to 1.0% compared to prior guidance of 0.0% to 2.0%.
<ul class="wp-block-list">
<li>Adjusted operating income rate of approximately 4.2%, compared to prior guidance of 4.2% to 4.4%.</li>
</ul>
Price Action: BBY stock is trading 2.54% lower at $69.70&nbsp;in premarket at the last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/large-cap/25/05/45665087/bp-announces-first-gas-at-mento-off-trinidads-southeast-coast" target="_blank" rel="noreferrer noopener">BP Announces First Gas At Mento Off Trinidad&#8217;s Southeast Coast</a></li>
</ul>

Large Cap

Trading Ideas

General

Best Buy Falls Short: Sales, Earnings Miss As Tariff Pressures Mount

Tigress Financial analyst Ivan Feinseth maintains Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) with a Buy and raises the price target from $244 to $250.

Price Target

Analyst Ratings

Tigress Financial Maintains Buy on Fiserv, Raises Price Target to $250

Macro Economic Events

WIIM

Economics

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher after a federal court has ruled against Trump's authority to impose extensive global tariffs under the International Emergency Economic Powers Act.

At what will be his <a href="https://www.benzinga.com/25/05/45187070/warren-buffett-retires-after-decades-of-dominancefrom-tim-cook-to-mark-cuban-worlds-top-business-leaders-react-to-the-investment-icons-exit">last annual meeting as CEO</a> of Berkshire Hathaway, Warren Buffett shared a story that succinctly demonstrated his unique ability to spot value in unexpected places, like a small Japanese handbook he could barely read.
What Happened: Buffett's famous journey with the <a href="https://www.benzinga.com/markets/bonds/25/05/45635713/warren-buffetts-cheap-debt-bet-on-these-japanese-stocks-is-minting-infinite-returns-fund-manager-calls-it-a-no-brainer">five Japanese trading houses</a> — Itochu, Marubeni, Mitsubishi Corp., Mitsui &amp; Co.and Sumitomo Corp. started not with a team of analysts or a visit to the country, but with a handbook detailing thousands of Japanese companies, <a href="https://www.cnbc.com/2025/05/26/what-you-may-have-missed-in-berkshires-last-annual-meeting-under-buffett.html">according </a>to CNBC. 
"I was just going through a little handbook that probably had 2,000 or 3,000 Japanese companies in it," he recalled. In it, he discovered a group of companies that caught his attention. "One problem I have is that I can't read that handbook anymore. The print's too small. And there were these five trading companies. They have a special name for them in Japan, but they were selling at ridiculously low prices. So I spent about a year acquiring them." 
Berkshire Hathaway now holds around 10% of each firm.
See Also: <a href="https://www.benzinga.com/general/education/25/05/45607543/warren-buffett-you-can-make-a-fortune-but-your-life-is-a-disaster-if-you-overlook-this-one-thing">Warren Buffett: You Can Make A Fortune, But &#8216;Your Life Is A Disaster&#8217; If You Overlook This One Thing</a>
Why It Matters: This handbook is the go-to source for Japan's everyday retail investors. Bloomberg <a href="https://www.bloomberg.com/opinion/articles/2025-05-12/buffett-s-little-japan-handbook-and-other-investing-lessons">reports</a> that it is known as the Kaisha Shikiho, a quarterly guide regarded locally as the "bible of Japanese equities." For about ¥2,800 (approximately $20), investors get a comprehensive, encyclopedia-style volume full of data on almost 4,000 publicly traded companies across Japan.
The English edition of the Handbook has even appeared on Buffett's desk more than ten years ago. But surprisingly, the publisher discontinued the English version last year.
Highlighting the value of the handbook, Buffett said: "If you get real opportunities every five or six years&#8230;, <a href="https://www.benzinga.com/general/education/25/05/45602754/warren-buffett-investment-success-3-simple-rules-to-copy-oracle-of-omaha">you have to be patient</a>." "Every now and then you get extraordinary opportunities, and most of the time you don't have much of an edge," he added.
Read Next: <a href="https://www.benzinga.com/tech/25/05/45661246/warren-buffett-loves-sees-candies-but-even-he-cant-get-the-brand-to-succeed-nationwide-heres-why">Warren Buffett Has Discovered There&#8217;s No Accounting For Tastes Through Berkshire&#8217;s Candy Company: &#8216;There Are All Kinds Of Crazy Things In The World That Consumers Do&#8217;</a>
Photo Courtesy: Photo Agency On Shutterstock

Equities

Markets

ITOCY

MARUY

MITSY

MTSUY

SSUMY

Warren Buffett Found Billions In A Tiny Japanese Guidebook He Could Barely Read — No Analysts, No Travel, Just Pure Instinct

Telsey Advisory Group analyst Dana Telsey maintains Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) with a Market Perform and maintains $9 price target.

Telsey Advisory Group Maintains Market Perform on Kohl's, Maintains $9 Price Target

D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) with a Buy and lowers the price target from $17 to $10.

IMUX

D. Boral Capital Maintains Buy on Immunic, Lowers Price Target to $10

- Safe &amp; Green Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) ("Safe &amp; Green Holdings" or the "Company"), a leading developer, designer, and fabricator of modular structures diversified platform transforming critical infrastructure through sustainable modular innovation, announces the acquisition of certain assets of Sherman Oil Company, LLC and several affiliatendividuals and entities that total 1,600 acres of oil wells and leases. The newly acquired assets are are reported to be producing an average of 45 barrels of oil per day.

SGBX

Safe & Green Holdings Acquires 1,600 Acres Of Producing Oil Wells And Leases From Sherman Oil And Affiliates, Adding 45 Barrels Per Day To Operations; No Financial Terms Disclosed

Keybanc analyst Eric Heath maintains C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) with a Underweight and raises the price target from $17 to $18.

Keybanc Maintains Underweight on C3.ai, Raises Price Target to $18

Telsey Advisory Group analyst Dana Telsey maintains Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) with a Outperform and maintains $340 price target.

BURL

Telsey Advisory Group Maintains Outperform on Burlington Stores, Maintains $340 Price Target

Webus International Limited ("Webus," the "Company," "we," "our," or "us") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETO#NASDAQ">WETO</a>), a recognized provider of AI-driven mobility solutions specializing in premium, customizable chauffeur services for travelers worldwide, today announced two complementary strategic developments that significantly advance its vision of a seamless, borderless travel ecosystem.&nbsp;
The Company is exploring a financing strategy of up to US$300 million (the "Financing") through a diversified mix of non-equity funding vehicles to establish an XRP reserve for supporting global payment solutions. This approach includes the potential use of available cash reserves, bank lending, shareholder guarantees, and third-party institutional-backed credit facilities from traditional banks. By leveraging these non-dilutive financing methods, the Company seeks to maintain capital flexibility, support long-term growth, and preserve shareholder value while advancing its strategic objective in the digital asset and cross-border paryment space. In addition, the Company renewed its nationwide mobility partnership (the "Partnership") with Tongcheng Travel Holdings Ltd. (HKSE: 0780.HK), one of China's largest online travel platforms.

Financing

WETO

Webus International Announces Strategic $300M Non-Equity Financing Plan To Establish XRP Reserve For Global Payment Solutions; Renews Nationwide Mobility Partnership With Tongcheng Travel

Offerings

BULL

BULLZ

Webull Issues Notice Of Redemption For All Outstanding Incentive Warrants Of 'BULLZ' To Be Redeemed On June 30, 2025 At $0.01 Per Warrant Unless Exercised At $10.00 Per Share Before Deadline

Agilent Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45656371/agilent-reports-second-quarter-fiscal-year-2025-financial-results" rel="noreferrer noopener">second-quarter 2025</a> sales of $1.67 billion on Wednesday, almost in line with the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.63 billion</a>, representing growth of 6% reported and up 5.3% core year-over-year.
The Life Sciences and Diagnostics Markets Group (LDG) reported second-quarter revenue of $654 million, an increase of 8% reported and 3% core&nbsp;year-over-year. LDG&#8217;s operating margin for the quarter was 19.7%.
The Agilent CrossLab Group (ACG) reported second-quarter revenue of $713 million, an increase of 7% reported and 9% core year-over-year. ACG&#8217;s operating margin for the quarter was 32.4%.
The Applied Markets Group (AMG) reported second-quarter revenue of $301 million, a decrease of 1% reported and flat core year-over-year. AMG&#8217;s operating margin for the quarter was 19.5%.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45655674/rocket-pharmas-gene-therapy-future-clouded-by-regulatory-uncertainty" rel="noreferrer noopener">Rocket Pharma&#8217;s Gene Therapy Future Clouded By Regulatory Uncertainty</a>
The <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">analytical and clinical laboratory</a> technologies provider reported adjusted earnings of $1.31 per share, up from $1.22 a year ago, beating the consensus of $1.26.
&#8220;The Agilent team delivered strong second-quarter results in a highly dynamic market environment,&#8221; said Agilent President and CEO Padraig McDonnell. &#8220;That is in large part due to our Ignite Transformation, which is driving our financial success as it&#8217;s become our core enterprise delivery engine and operating model. Ignite represents a decisive shift to fuel accelerated profitable growth and operational excellence at Agilent.&#8221;
The company&#8217;s&nbsp;operating margin <a target="_blank" href="https://in.investing.com/news/transcripts/earnings-call-transcript-agilent-technologies-q2-2025-beats-forecasts-stock-rises-93CH-4852010" rel="noreferrer noopener">was</a> 25.1% as it absorbed some incremental tariff costs.
In the earnings conference call, McDonnell said, &#8220;Through our tariff task force enabled by our Ignite operating model, we feel that we are able to mitigate most of the impact in 2025 and fully mitigate in 2026 even when considering recent developments on the U.S.-EU tariffs.&#8221;
Agilent reaffirmed fiscal 2025 adjusted earnings of $5.54-$5.61 per share compared to the consensus of $5.55.
The company raised sales guidance from $6.68 billion-$6.76 billion to $6.73 billion-$6.81 billion compared to the consensus of $6.73 billion.
The full-year revenue outlook represents growth of 3.4%-4.6% reported while maintaining core growth of 2.5%-3.5%
Based on the current tariff rates, Agilent estimates that the gross incremental tariff exposure in the second half will be $50 million. This is on top of the roughly $10 million already absorbed in the first half.
The company anticipates potential additional tariff impacts if U.S.-EU tariffs increase, which could add $40 million in gross exposure in the second half of 2025.
The outlook for third-quarter revenue is expected to be $1.65 billion-$1.68 billion versus a consensus of $1.65 billion, representing a growth of 4.2% to 6.1% reported and up 1.7% to 3.6% core.
Agilent sees Q3 adjusted earnings of $1.35-$1.37 versus a consensus of $1.39.
Price Action: A stock is trading higher by 5.52% to $117 premarket at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/health-care/25/05/45634160/elon-musks-neuralink-hits-9-billion-valuation-with-new-funding" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s Neuralink Hits $9 Billion Valuation With New Funding</a></li>
</ul>
Image via Shutterstock

Health Care

Agilent Braces For Potential US-EU Tariff Hike, Maintains Annual Outlook

PepGen Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) announced on Wednesday that it will focus on advancing its myotonic dystrophy type 1 (DM1) program, currently in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45656401/pepgen-to-focus-on-development-of-promising-dm1-program-following-10-mgkg-pgn-edo51-update" rel="noreferrer noopener">Phase 2 clinical development</a>.
The company voluntarily discontinued the development of PGN-EDO51 and intends to wind down all Duchenne muscular dystrophy (DMD)-)-related research and development activities.
The decision is based on the levels of dystrophin protein measured in the 10 mg/kg cohort of its CONNECT1-EDO51 study of PGN-EDO51 in DMD patients amenable <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">to exon 51 skipping</a>.
In the CONNECT1 study&#8217;s 10 mg/kg cohort (n=4), PGN-EDO51 increased exon 51 skipped transcripts to 4.26% (a mean increase of 3.5%); however, total dystrophin only increased to 0.59% of normal levels (a mean increase of 0.36%).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44120665/pepgen-to-voluntarily-pause-mid-stage-duchenne-muscular-dystrophy-study-stock-falls" rel="noreferrer noopener">PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls</a>
The safety profile of PGN-EDO51 continued to be generally favorable and all treatment-related adverse events were mild. No serious adverse events were reported in the study.
&#8220;We are disappointed by the dystrophin results observed in the 10 mg/kg dose cohort in CONNECT1, as it was our hope that we could improve upon existing therapies for patients in a more profound way,&#8221; said James McArthur, president and CEO of PepGen.
Paul Streck, executive vice president and head of R&amp;D at PepGen, continued, &#8220;PGN-EDODM1, PepGen&#8217;s investigational drug in development for DM1, has already demonstrated robust target engagement after a single 10 mg/kg dose in patients that resulted in mean mis-splicing correction of 29% with a favorable emerging safety profile as of February 24, 2025, the most recent safety update.&#8221;
PepGen expects to report data from its FREEDOM-DM1 15 mg/kg cohort in patients with DM1 during the second half of 2025. FREEDOM is a Phase 1 single ascending dose, randomized, placebo-controlled clinical trial, with endpoints including safety, 28-day splicing correction, and functional benefit measures.
The company also expects to report data from the 5 mg/kg cohort of its FREEDOM2-DM1 study in DM1 patients in the first quarter of 2026. FREEDOM2 is a Phase 2 multiple ascending dose, randomized, placebo-controlled clinical trial with endpoints following four doses, including safety, splicing correction, and functional benefit measures.
Price Action: At the last check on Thursday, PEPG stock was down 6.69% at $1.47 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45658018/box-growth-from-large-deals-partner-expansion-and-new-pricing-lifts-wall-street-outlook" target="_blank" rel="noreferrer noopener">Box Growth From Large Deals, Partner Expansion, And New Pricing Lifts Wall Street Outlook</a></li>
</ul>
Photo: Shutterstock

Biotech

PEPG

PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate

Galxe recently announced the launch of a new community engagement platform, <a href="https://www.benzinga.com/topic/web3">dubbed "Starboard."</a>
But the new platform is no hard turn for the company, which claims to have onboarded 34 million users into Web3 through its Quest platform. With the new platform, they intend to transition their customer onboarding presence into community management. "Starboard represents an additional level to this core capability, giving projects more insight into their communities that they can use to drive powerful growth," Galxe&#8217;s Head of GTM Patrick Young says.
See Also: <a href="https://www.benzinga.com/25/05/45668187/nvidia-faces-bipartisan-backlash-over-its-shanghai-facility-amid-significant-national-and-economic-security-threat-report">Nvidia Faces Bipartisan Heat Over Its Shanghai Facility Amid &#8216;Significant&#8217; National And Economic Security Threat</a>
Galxe has positioned Starboard as distinct from competitors like Layer3, Zealy, and RabbitHole. It tracks the life cycle of the client using an "Aura" score for off-chain metrics, like the impact of a social media post, alongside on-chain metrics like trading volume, TVL growth, and more.
"Galxe has always played a broader role in web3 growth, offering not only tools for initial engagement but also infrastructure for identity verification, distribution of rewards for long-term community members, and more," Young said. "With Starboard, teams can now double down on their highest-value contributors, allowing them to build highly engaged, long-term communities."
Galxe teamed with 20 Web3 companies in this launch. Plume Network, 0G Labs, Dango, RollDex, KRNL, Vanilla Finance, GRVT, Irys, Quranium, Lightlink, Zeta Chain, Cooking City, ChainOpera AI, Aspecta, Zerobase, Bitfi, Analog, Dabba Network and SPACE ID are among its partners.
Plume Network has contributed $450,000 to the collective rewards pool. Dango has committed 1 percent of its total token supply, and OG Labs has committed over $100,000. 
"Similar to Galxe Quest, which has found success through a model where projects fund reward pools to incentivize user participation. Starboard operates on the same principle. Projects provide reward pools to attract core contributors to support and grow their ecosystems, which is a fundamental, ongoing need," Young said.
Young pointed out that as more projects join the platform, the dataset will expand, and the accumulated data will become increasingly valuable to the Web3 market.
It's questionable whether a community can truly be the utility of a project. As many memecoin projects suggested in 2024, the community is one of the most powerful assets of any Web3 project. Observers consider tools like this part of the maturation of the blockchain space. As we grow, we need to know ourselves and our customers better, on-chain and off. It remains to be seen whether Galxe will successfully establish the new platform as a standard for blockchain projects. Whether their data moat will become a true differentiator in a crowded market of Web3 growth tools is also uncertain. Still, solutions like this will be in demand as blockchain technology becomes more mainstream.
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45667896/hedera-co-founder-predicts-that-everything-of-value-will-be-tokenized">Hedera Co-Founder Predicts That &#8216;Everything Of Value&#8217; Will Be Tokenized</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Fintech news covering the emerging Financial Technology services sector

Fintech

Exclusives

Tech

Interview

Galxe Launches New Web3 Community Building Platform

Euroseas Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESEA#NASDAQ">ESEA</a>, the "Company" or "Euroseas"))), an owner and operator of container carrier vessels and provider of seaborne transportation for containerized cargoes, announced today that it has signed an agreement to sell M/V Marcos V, an 6,350 teu intermediate containership built in 2005, to an unaffiliated third party, for $50 million. The vessel is scheduled to be delivered to its buyer in October 2025. The Company is expected to recognize a gain on the sale in excess of $8.50 million, or $1.20 per share.

Asset Sales

ESEA

Euroseas Signs Agreement To Sell 6,350 Containership M/V Marcos V For $50M, With Expected Gain Of Over $8.5M Or $1.20 Per Share Upon October 2025 Delivery

A Reddit user claims he took $100,000 from a recent <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/04/44658576/more-homes-hit-the-market-but-pending-sales-dip-as-buyers-hesitate">house sale</a> and put it all into UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) stock without telling his wife, who believes the money is safely tucked away in a <a href="https://www.benzinga.com/money/best-high-yield-savings-accounts">high-yield savings account</a>.
<h2 class="wp-block-heading">A High-Stakes Secret</h2>
In the popular <a href="https://www.reddit.com/r/wallstreetbets/comments/1kt8b8d/i_took_100k_from_our_house_sale_and_bought_303/">r/wallstreetbets</a> subreddit, the investor wrote, &#8220;Wife said, ‘Put it somewhere safe.' I said, hold my beer b&#x2A;tch, then funneled $100K into <a href="https://www.benzinga.com/money/fidelity-investments-review">Fidelity</a> and bought 303 shares of UnitedHealth.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
He justified the risky move by saying, &#8220;Because America's not gonna stop getting sick. Fat, old, diabetic, stressed out, healthcare is the last thing people cut. And UNH is built like a tank. Major insider buying too.&#8221;
UnitedHealth stock was down over 41% year to date when the UNH investor posted about his investment late May 22.&nbsp;
The r/wallstreetbets comment section exploded with reactions, ranging from jokes about impending divorce to harsh warnings. The top comment read, &#8220;Make sure you put something aside to pay for your divorce lawyer,&#8221; to which OP replied, &#8220;I still have the $20K… it's either for the lawyer or <a href="https://www.benzinga.com/money/options-trading-strategies">call options</a>.&#8221;
Another comment read, &#8220;You don't need a lawyer if there's nothing left to fight over,&#8221; while another person remarked, &#8220;This is the f&#x2A;&#x2A;ing sh&#x2A;t I signed up for,&#8221; reflecting the subreddit's mix of chaos, comedy, and high-risk investing.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
Others chimed in with classic WallStreetBets flair: &#8220;<a href="https://www.benzinga.com/25/05/45308441/risk-appetite-hits-record-high-0dte-options-hit-67-of-total-volumes2-million-average-contracts-in-q1">0dte puts</a> on this guy's marriage at open,&#8221; and &#8220;Big Balls, Big Calls.&#8221;&nbsp;
Critics, though, pointed to the serious implications. &#8220;If a financial decision needs to be hidden from your <a href="https://www.benzinga.com/personal-finance/24/03/37879066/kevin-oleary-warns-couples-maintain-your-own-financial-identity-but-indiana-university-study-say">significant other</a>, that&#8217;s usually a good indication that it&#8217;s dumb,&#8221; one comment noted. Another added, &#8220;That's financial infidelity. Your marriage is done.&#8221;
<h2 class="wp-block-heading">Inside the UNH Crisis</h2>
Meanwhile, UnitedHealth has <a href="https://www.benzinga.com/25/05/45558758/as-unitedhealth-group-lost-an-unthinkable-140-billion-in-market-cap-since-april-analysts-weigh-in-on-the-path-ahead">had a rough stretch</a>. The company missed earnings expectations last quarter and is under pressure from several fronts. It abruptly <a href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance">replaced its CEO</a>, Andrew Witty, with former CEO Stephen Hemsley. Hemsley then <a href="https://www.benzinga.com/general/health-care/25/05/45486314/unitedhealth-ceo-other-insiders-buy-millions-in-stock-as-it-sinks-over-23-in-a-week-move-gets-mixed-reaction">bought in $25 million worth of shares</a>, joining other insiders who collectively purchased millions more in stock.
According to <a href="https://www.secform4.com/insider-trading/731766.htm">filings</a> with the Securities and Exchange Commission, board members Timothy Flynn, Kristen Gil and John Noseworthy purchased shares worth $49,786, $1,003,329 and $93,647, respectively. CFO John Rex added another $5 million.
It also remains under a shadow after the December <a href="https://www.benzinga.com/24/12/42322999/unitedhealth-deeply-saddened-and-shocked-by-death-of-brian-thompson-new-york-police-share-update-on-case-with-10k-reward-offered-rockefeller-center-tree-lighting-to-go-on">assassination</a> of its insurance unit CEO, Brian Thompson.&nbsp;
See Also: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
<h2 class="wp-block-heading">Mixed Sentiment From Investors</h2>
Despite all this, some investors see a long-term opportunity. One commenter argued, &#8220;UNH is too big to fail. The stock will go back up over the next couple years.&#8221;
Others are more skeptical. Investment YouTuber Jeremy Lefebvre called the stock &#8220;straight trash&#8221; <a href="https://x.com/HolySmokas/status/1923806928951775450">on X</a>, comparing it to Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) and warning that UnitedHealth is entering a long stretch of regulatory trouble and bad press.
However, the original poster seems to agree with the bulls, doubling down with: &#8220;I'm not finished. Let's see how the stock moves. I will keep you posted.&#8221;
As of now, his wife is still in the dark.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

'America's Not Gonna Stop Getting Sick,' Says Investor Who Put $100K Into UNH Stock. His Wife Still Thinks It's Sitting In A Savings Account

LTRN

LTRN stock has given up its prior gain. Lantern Pharma shares were trading higher after the company announced preclinical data for LP-184.

Inspira&#x2122; Technologies OXY B.H.N. Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IINN#NASDAQ">IINN</a>) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced a strategic shift to accelerate the commercialization of its U.S. FDA (Food and Drug Administration)-cleared INSPIRA&#x2122; ART100 system (the "ART100"), while maintaining the development and regulatory pathways of its portfolio of products. The Company is currently engaged in active sales discussions in multiple locations.
This development follows the initial clinical implementation of the ART100 system in medical centers in the U.S., where the device has been used to treat patients in real-world clinical settings.

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

Inspira Technologies Announces Strategic Shift To Accelerate Commercialization Of FDA-Cleared INSPIRA ART100 System, While Maintaining Development, Regulatory Pathways Of Its Portfolio

Press Releases

Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer ("SITC") 2024 Annual Meeting

Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy

Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Management

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates

ELTX

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Alector

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Atossa Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Cellectis S.A. - American Depositary Shares

Cellectis

Caribou Biosciences

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

EXoZymes

Fate Therapeutics

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

TuHURA Biosciences

Korro Bio

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Liminatus Pharma, Inc. - Class A Common Stock

Liminatus Pharma

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lyell Immunopharma

Nkarta

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

RAPT Therapeutics

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Spero Therapeutics

Protara Therapeutics, Inc. - Common Stock

Comments

Elicio Therapeutics

Elicio Therapeutics (ELTX) オプション

Elicio Therapeutics (NASDAQ:ELTX) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル